Ticketplus Squeezes Onto NYSE American at a Deep Haircut as the Small-IPO Window Stays Open — but Picky
The IPO window for genuinely small companies is open in 2026 — but the toll booth is charging heavily. The latest evidence is Ticketplus Ltd. (NYSE American: TP), a Santiago, Chile-based live-event ticketing platform that began trading August 7 after pricing 1,875,000 ordinary shares at $8.00 apiece for gross proceeds of approximately $15 million, according to the company's pricing release carried by StockTitan. The offering closed on August 10, per the company's announcement distributed by GlobeNewswire.
Getting there required two rounds of concessions. Ticketplus originally marketed the deal at $13 to $15 per share before cutting the range to $8 to $10 — a move Renaissance Capital calculated as a roughly 33% reduction in deal size and a 35% cut to the company's fully diluted market value, which stood near $113 million at the revised midpoint. The final $8.00 price sat at the bottom of even that reduced range, and StockTitan pegged the post-IPO market capitalization at roughly $91 million. Roth Capital Partners, Bancroft Capital and MDB Capital ran the books.
The business itself is a real one by nano-cap IPO standards. Ticketplus operates a full-stack platform spanning ticket discovery, primary ticketing, access control, payments and analytics for live entertainment across eleven Latin American countries including Chile, Mexico and Colombia, and generated $29 million in revenue in the twelve months ended December 2025, per Renaissance Capital. That is more operating substance than many companies arriving on US exchanges at this size — which makes the valuation surgery required to complete the deal all the more telling.
Early trading has extended the discount. Ticketplus shares closed at $7.00 on Tuesday, down 12.5% from the offer price, according to StockAnalysis IPO data — a reminder that pricing below the range is not always enough to leave room for a first-week pop.
The contrast with the rest of the week's calendar was stark. Braveheart Bio (BRVE) priced at $18 on August 6 and traded to $30 by Tuesday, a 67% gain, while Attovia Therapeutics (ATTO) rose about 19% from its $17 offer and Latigo Biotherapeutics (LTGO) and BlossomHill Therapeutics (BLSM) both priced $16-to-$18 deals, per StockAnalysis. Institutional appetite for clinical-stage biotech at $18 a share is demonstrably intact; appetite for an $8 nano-cap consumer-tech deal required a one-third valuation cut to materialize.
The week also underscored how thoroughly blank-check issuance has returned to the small-cap ecosystem. Four special-purpose acquisition companies listed within five sessions — Pinnacle Acquisition (PNAQ), TCGX Acquisition (TCGX), ARC Group Securities Acquisition I (FJDI) and BOA Acquisition II (THEO) — with TCGX already trading 27% above its $10 trust price, per StockAnalysis. Each of those vehicles will eventually need a private company to take public, and micro-cap-sized targets are where most SPAC searches end.
For the micro-cap ecosystem, the week's ledger is mixed but readable. Deals are getting done across the size spectrum, from $15 million nano-cap raises to upsized biotech offerings, and the SPAC pipeline is refilling. But the Ticketplus experience — two price cuts, a bottom-of-range print and a below-issue first week — shows the market is discriminating sharply on size and story. Companies eyeing this window should note that it is open on the market's terms, not the issuer's.
